Results 161 to 170 of about 5,419,102 (403)

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Metabolism of sulphur [PDF]

, 1937
Grace Medes
openalex   +1 more source

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease

Cell, 2017
B. Stockwell, J. Angeli, H. Bayır, A. Bush, M. Conrad, S. Dixon, S. Fulda, S. Gascón, Stavroula K. Hatzios, V. Kagan, Kay Noel, Xuejun Jiang, A. Linkermann, M. Murphy, M. Overholtzer, Atsushi Oyagi, G. Pagnussat, Jason Park, Qitao Ran, C. Rosenfeld, K. Salnikow, D. Tang, D. Tang, F. Torti, S. Torti, S. Toyokuni, K. Woerpel, Donna D. Zhang   +27 more
semanticscholar   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

The Emerging Hallmarks of Cancer Metabolism.

Cell Metabolism, 2016
N. Pavlova, C. Thompson
semanticscholar   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Stimulation of oxygen consumption following addition of lipid substrates in liver and skeletal muscle from rats fed a high fat diet. [PDF]

, 1999
IOSSA, SUSANNA, LIVERINI, GIOVANNA, MOLLICA, MARIA PINA, Soboll S.   +3 more
core   +1 more source

A STUDY OF HEMOGLOBIN METABOLISM IN PAROXYSMAL HEMOGLOBINURIA [PDF]

, 1922
Chester M. Jones
openalex   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Lipid metabolism

Current Opinion in Lipidology, 1999
Fielding, BA, Frayn, KN
openaire   +9 more sources